S. 932 · 119th Congress · Health

Give Kids a Chance Act of 2025

In committee1.8k words Introduced Mar 11, 2025 · Latest action Mar 11, 2025

How far it has goneStage 2 of 6
  1. IntroducedMar 11, 2025 Done
  2. CommitteeReferred to Health, Education, Labor, and Pensions Current stage
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases.

Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.

The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.

The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024.

GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.

Congressional Research Service · summary of “Introduced in Senate” version · Mar 11, 2025

Who lobbies on it

15 organizations, more than 98% of Senate bills · 74 filings · Q1 2025–Q3 2026

These 15 organizations’ PACs gave $136K to 10 of the 17 members sponsoring or cosponsoring S. 932 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the Senate → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Ptc Therapeutics, Inc. 7 of 7 quarters
    “…S.932 - Give Kids a Chance Act of 2025.”

    $730K lobbying spend in 2026 to date, all issuesQ3 2026 filing

  2. Healthcare Institute of New Jersey 7 of 7 quarters
    “…Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule…”

    $148K lobbying spend in 2026 to date, all issuesQ3 2026 filing

  3. Biotechnology Innovation Organization (bio) 6 of 7 quarters
    “Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.”

    $6.5M lobbying spend in 2026 to date, all issuesQ2 2026 filing

12 more organizations, every filingPROUpgrade

Organizations that named S. 932 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Mar 11, 2025Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  2. Mar 11, 2025Introduced in Senate